Pre-made Fresolimumab benchmark antibody ( Whole mAb, anti-TGFB/TGFB1 therapeutic antibody, Anti-CED/DPD1/IBDIMDE/LAP Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-223

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-223 Category Tag

Product Details

Pre-Made Fresolimumab biosimilar, Whole mAb, Anti-TGFB/TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fresolimumab (GC1008) is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).

Products Name (INN Index)

Pre-Made Fresolimumab biosimilar, Whole mAb, Anti-TGFB/TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody

INN Name

Fresolimumab

Target

TGFB1

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG

95-98% SI Structure

None

Year Proposed

2009

Companies

Cambridge Antibody Technology,Baylor College of Medicine,Genzyme Corporation,Sanofi Genzyme

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Fibrosis,Malignant melanoma,Pulmonary fibrosis,Renal cancer,Focal segmental glomerulosclerosis,Osteogenesis imperfecta

Development Tech

CAT Phage Display

Previous Name

NA

Gm Offical Target Name

TGFB

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide